December 19, 2017 / 1:22 PM / 6 months ago

BRIEF-Rucaparib MAA Referred By CHMP To Scientific Advisory Group On Oncology For Review

Dec 19 (Reuters) - Clovis Oncology Inc:

* RUCAPARIB MAA FOR THE OVARIAN CANCER TREATMENT INDICATION REFERRED BY CHMP TO SCIENTIFIC ADVISORY GROUP ON ONCOLOGY FOR REVIEW EXPECTED IN FEBRUARY 2018

* CLOVIS ONCOLOGY INC - IN JANUARY 2018, COMPANY PLANS TO NOTIFY EMA OF ITS INTENT TO SUBMIT A NEW MAA IN Q2 2018

* CLOVIS ONCOLOGY - PLANS TO NOTIFY EMA OF INTENT TO SUBMIT A NEW MAA FOR MAINTENANCE TREATMENT INDICATION IN WOMEN WITH ADVANCED OVARIAN CANCER

* CLOVIS ONCOLOGY INC - EXACT DATE FOR SAG MEETING HAS NOT YET BEEN SET BUT WE EXPECT IT TO TAKE PLACE IN EARLY FEBRUARY 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below